Cardiovascular advantages of a third generation calcium antagonist. Symposium on lacidipine. Foreword.
作者信息
Zanchetti A
机构信息
Istituto di Clinica Medica Generale e Terapia Medica, Università di Milano, Ospedale Maggiore, Milan, Italy.
出版信息
Drugs. 1999;57 Suppl 1:2 p preceding 1.
PMID:10529077
Abstract
摘要
相似文献
1
Cardiovascular advantages of a third generation calcium antagonist. Symposium on lacidipine. Foreword.
Drugs. 1999;57 Suppl 1:2 p preceding 1.
2
[Drug information about lercanidipine. A new dihydropyridine calcium antagonist for the treatment of arterial hypertension].
Ugeskr Laeger. 2005 Jan 10;167(2):153-5.
3
[Hypertension in type 2 diabetic patients. Calcium antagonist supports the left heart].
MMW Fortschr Med. 2001 Jun 21;143(25):58.
4
Calcium channel blocker.
Clin Ther. 2010 Feb;32(2):396; author reply 397. doi: 10.1016/j.clinthera.2010.02.007.
5
[Also for problem cases; successful first line therapy].
MMW Fortschr Med. 2005 Feb 3;147(5):47.
6
Lacidipine. Aponil, Caldine, GR 43659, GR 43659X, GX 1048, Lacimen, Lacipil, Lacirex, Midotens, Motens, SN 305, Viapres.
Drugs R D. 2002;3(5):324-30. doi: 10.2165/00126839-200203050-00006.
7
Safety profile of lacidipine: a review of clinical data.
J Cardiovasc Pharmacol. 1991;17 Suppl 4:S45-7.
8
[Third generation of calcium antagonists: focus on lacidipine].
Kardiologiia. 2002;42(12):81-90.
9
[Dihydropyridines for treatment of arterial hypertension].
Pharm Unserer Zeit. 2005;34(5):388-91. doi: 10.1002/pauz.200500137.
10
[Lercanidipine, a third generation calcium antagonist. Which advantages?].
Rev Med Suisse. 2006 Sep 13;2(78):2047-50, 2052-3.
Zotero 插件